10-Q: Quanterix Q3 Loss Widens Amid Akoya Integration, Macro Headwinds

Quanterix reported a significantly wider net loss in Q3 2025, driven by acquisition costs, restructuring, and macroeconomic pressures, despite revenue growth from the Akoya Biosciences acquisition.

Summary

• Net loss for the three months ended September 30, 2025, was $33.5 million, a significant increase from $8.4 million in the same period of 2024.
• Net loss for the nine months ended September 30, 2025, was $84.0 million, up from $26.9 million in the same period of 2024.
• Total revenues increased 12% to $40.2 million in Q3 2025, but decreased 7% to $95.0 million for the nine months ended September 30, 2025, compared to the prior year periods.
• Product revenue increased 33% to $26.2 million in Q3 2025, primarily due to the Akoya acquisition adding $11.3 million. Legacy Quanterix product revenue decreased $4.8 million (25%).
• Service revenue increased 1% to $14.0 million in Q3 2025, with Akoya contributing $5.9 million (including $1.2 million non-cash revenue). Legacy Quanterix service revenue decreased $5.8 million (42%).
• A goodwill impairment charge of $6.4 million was recorded in Q2 2025 due to declining revenue and bookings from macroeconomic conditions.
• Restructuring costs of $7.2 million were incurred in Q3 2025, related to severance and a leased facility impairment, as part of a plan to reduce annualized operating expenses by $67.0 million, with a goal of $85.0 million.
• Acquired Akoya Biosciences, Inc. on July 8, 2025, for $151.0 million (including $49.2 million in stock, $18.9 million cash, and $82.1 million for debt extinguishment), expanding into spatial biology solutions.
• Acquired Emission, Inc. on January 8, 2025, for $16.6 million (including $9.0 million cash, $1.0 million holdback, and $6.6 million contingent consideration), securing proprietary magnetic beads.
• Cash, cash equivalents, and marketable securities totaled $134.8 million as of September 30, 2025.
• ISO 13485 certification was received on January 31, 2025, for Billerica, Massachusetts operations.
• Ongoing material weaknesses in internal control over financial reporting related to inventory valuation and Accelerator Revenue persist.

Sentiment

Score: 3

Explanation: The company is undergoing significant strategic expansion through acquisitions, but this is overshadowed by substantially increased net losses, a goodwill impairment, and ongoing material weaknesses in internal controls. While there are efforts to reduce costs and a positive long-term outlook for the combined entity, current financial performance and operational challenges indicate a negative short-term sentiment.

Positives

• Total revenues increased by 12% to $40.2 million in Q3 2025, primarily driven by the Akoya acquisition.
• Product revenue saw a 33% increase to $26.2 million in Q3 2025, with Akoya contributing $11.3 million.
• Strategic acquisitions of Akoya Biosciences and Emission, Inc. expanded the company's portfolio into spatial biology and secured key manufacturing technology.
• ISO 13485 certification for Billerica operations indicates a strong quality management system for medical device manufacturing.
• Restructuring efforts are expected to reduce annualized operating expenses by $67.0 million, with a goal of $85.0 million, aiming for cash flow breakeven in 2026.
• An income tax benefit of $2.5 million in Q3 2025 and $5.5 million for the nine months was recognized, primarily due to the release of a valuation allowance on deferred tax assets from the Akoya acquisition.

Negatives

• Net loss significantly widened to $33.5 million in Q3 2025 from $8.4 million in Q3 2024, and to $84.0 million for the nine months from $26.9 million in the prior year.
• Total revenues for the nine months ended September 30, 2025, decreased by 7% compared to the same period in 2024.
• Legacy Quanterix business experienced a $4.8 million (25%) decrease in product revenue and a $5.8 million (42%) decrease in service revenue in Q3 2025, attributed to reduced US federal research funding and pharmaceutical R&D spending.
• A goodwill impairment charge of $6.4 million was recorded in Q2 2025.
• Impairment and restructuring costs totaled $7.2 million in Q3 2025 and $14.8 million for the nine months.
• Selling, general and administrative expenses increased significantly by $16.2 million (71%) in Q3 2025 and $29.8 million (41%) for the nine months, partly due to acquisition and integration costs.
• Interest income decreased by $2.1 million (59%) in Q3 2025 and $3.8 million (34%) for the nine months due to lower interest rates and reduced cash/marketable securities balances.
• Ongoing material weaknesses in internal control over financial reporting related to inventory valuation and Accelerator Revenue persist.
• Cash used in operating activities increased to $60.8 million for the nine months ended September 30, 2025, from $30.9 million in the prior year.

Risks

• Integrating Akoya's business may be more difficult, costly, or time-consuming than expected, potentially failing to realize anticipated benefits and adversely affecting business results and stock value.
• Failure to remediate material weaknesses in internal control over financial reporting could lead to material misstatements, loss of investor confidence, regulatory scrutiny, and increased costs.
• The restatement of financial statements may affect investor confidence, harm reputation, and lead to increased costs, legal proceedings, and regulatory inquiries.
• Quarterly and annual operating results and cash flows have fluctuated and may continue to fluctuate, causing common stock value to decline.
• Continued annual losses are expected into 2026, and profitability is not guaranteed.
• Failure of products to achieve and sustain sufficient market acceptance will adversely affect revenue.
• Significant decrease in sales of neurological assays could materially harm the business.
• Challenges in penetrating the diagnostics market, including significant investments, complex regulatory frameworks, competition, and reimbursement issues.
• Lengthy and variable sales cycle for instruments makes revenue forecasting difficult.
• Reliance on a few large customers means any significant decrease in sales to them could harm operating results.
• Inability to improve existing products or successfully introduce new ones (e.g., Simoa ONE) in a timely manner.
• Delays in launching the next-generation Simoa ONE instrument could adversely affect the business.
• Defects or quality issues in products could lead to unforeseen costs, recalls, adverse regulatory actions, negative publicity, and litigation.
• Reliance on single contract manufacturers for key instruments (STRATEC for HD-X, Paramit for SR-X, Columbia Tech for PhenoCycler/PhenoImager, and a new one for Simoa ONE) poses supply chain risks.
• Reliance on a limited number of suppliers for materials and components for consumable products and instruments.
• Significant competition in the life sciences research and diagnostic markets.
• Changes in U.S. government policies, including reduced federal research funding and increased tariffs, adversely affecting the business.
• Potential for FDA to regulate products as medical devices or LDTs as devices, leading to expensive, time-consuming, and uncertain regulatory approval processes.
• Inability to protect intellectual property could reduce technological or competitive advantage.
• Risks related to intellectual property licensed from third parties (Tufts, Stanford, University of Washington, Revvity), including potential for licensors not acting in best interest or disputes.
• Potential for lawsuits alleging infringement of third-party intellectual property rights.
• Inability to protect intellectual property rights globally.
• Risks associated with third-party software and open source software.
• Market price of common stock has fluctuated significantly and may continue to do so.
• No dividends anticipated in the foreseeable future.
• Anti-takeover provisions in corporate documents and Delaware law could impair takeover attempts.

Future Outlook

Expects to incur operating losses into 2026, with a goal for the combined company to be cash flow breakeven in 2026, dependent on meeting revenue and expense objectives. Anticipates launching an early access program for the next-generation Simoa ONE instrument by the end of 2025. Expects softness in instrument sales and fluctuations in consumable sales to continue for the remainder of 2025 due to a constrained capital funding environment and uncertain macroeconomic conditions. Plans additional steps to further reduce annualized operating expenses to approximately $85.0 million by Q1 2026.

Management Comments

• "Believe that our continued investment in research and development is essential to our long-term competitive position."
• "Expect that the realization of anticipated synergies from the acquisition of Akoya should enable us to maintain research and development expense at a more consistent level period to period in the future."
• "Expect softness in instrument sales to continue in the remainder of 2025 as a result of what we believe is a constrained capital funding environment."
• "Anticipate a recovery in instrument demand as funding conditions improve."
• "Expect the uncertain macro-economic environment to cause fluctuations in consumable sales for the remainder of 2025."
• "While we continue to see strong opportunities with customers, the uncertain macro-economic environment is expected to continue to drive fluctuations in Accelerator Laboratory revenue in the remainder of 2025."
• "Believe our cash, cash equivalents, and marketable securities, along with funds generated from sales of our products and services, will be sufficient to meet our anticipated operating cash requirements for at least 12 months from the date of this Quarterly Report on Form 10-Q."
• "Expect the combined company will be cash flow breakeven in 2026, although our ability to achieve this goal is dependent on our success in meeting both revenue and expense objectives."

Industry Context

The company is expanding its presence in the life sciences research and diagnostics markets through strategic acquisitions, notably entering spatial biology with Akoya. This move positions the company to offer integrated solutions across tissue and blood biomarker analysis, aligning with broader industry trends towards comprehensive multi-omic approaches in disease understanding. However, the industry faces headwinds from reduced US federal research funding and slower R&D spending by pharmaceutical companies, impacting demand for instruments and services.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any pending or threatened litigation, the outcome of which would be expected to have a material adverse effect on its financial condition or results of operations.

Related Party Transactions

• Akoya has a diagnostic development agreement with a biopharmaceutical customer where a Quanterix Board member also serves on the customer's Board. Revenue from this customer was $2.3 million for both the three and nine months ended September 30, 2025, with cost of product revenue of $2.7 million for both periods.
• Agreements with two entities owned by Emission selling shareholders for development work on future products. Operating expense incurred was $0.3 million during the nine months ended September 30, 2025.
• Harvard University License Agreement: Harvard is required to pay a portion of payments received from Quanterix to a Quanterix Board member. Revenue from Harvard and Mass General Brigham was $0.4 million for the three months ended September 30, 2025, and $0.9 million for the nine months ended September 30, 2025.
• Tufts University License Agreement: A Quanterix Board member previously affiliated with Tufts continues to receive compensation from Tufts based on royalties and license payments made by Quanterix. Royalty expenses related to Tufts were $0.3 million for the three months ended September 30, 2025, and $1.1 million for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Significant net losses, goodwill impairment, and ongoing internal control issues could negatively impact share price and investor confidence. Potential dilution from future capital raises. Board declassification and majority voting standard could increase shareholder influence.
• Employees: Reductions in force as part of restructuring plans will impact employees through severance and job eliminations. Integration of Akoya employees.
• Customers: Potential for improved product offerings and integrated solutions through acquisitions. Softness in instrument sales and fluctuations in consumable sales due to macroeconomic conditions could affect customer purchasing decisions. Product quality issues or delays in Simoa ONE launch could lead to dissatisfaction.
• Suppliers/Partners: Reliance on single contract manufacturers and limited suppliers poses risks if these relationships are disrupted.
• Creditors: Increased net losses and cash burn from operations could be a concern, though current liquidity is deemed sufficient for 12 months.

Next Steps

• Continue integration of Akoya Biosciences.
• Take additional steps to further reduce operating expenses during the remainder of 2025 and into Q1 2026, aiming for $85.0 million in annualized savings.
• Launch an early access program for the next-generation Simoa ONE instrument by the end of 2025.
• Remediate material weaknesses in internal control over financial reporting related to inventory valuation and Accelerator Revenue.
• Identify and appoint a potential candidate to the Board of Directors by December 1, 2025, as per the Cooperation Agreement.
• Work towards achieving cash flow breakeven for the combined company in 2026.
• Continue development work on certain future products for Quanterix with entities owned by Emission selling shareholders.
• Co-develop, validate, seek regulatory approval for, and commercialize Acrivon's OncoSignature test on Akoya's PhenoImager HT solution.
• Evaluate and meet new technical requirements for Uman's NfL ELISA kit for CSF to comply with the IVD Regulation by May 2027.

Key Dates

Recommendation

While Quanterix is making strategic moves to expand its market presence through the Akoya and Emission acquisitions, the immediate financial results are concerning, with significantly widened net losses and a goodwill impairment. The ongoing material weaknesses in internal controls add a layer of operational risk. However, the company has a clear plan for cost reduction and aims for cash flow breakeven in 2026, and the strategic expansion into spatial biology offers long-term growth potential. Given the current challenges but also the strategic initiatives and future outlook, a 'hold' recommendation is appropriate for investors to monitor the execution of the integration, cost-saving measures, and remediation of internal control issues before making further investment decisions.

Keywords

life sciences, digital immunoassay, spatial biology, diagnostics, biomarkers, Simoa, Akoya, PhenoCycler, PhenoImager, SEC filing, 10-Q, financial results, corporate governance, restructuring, goodwill impairment, internal controls, biotechnology, neurology, oncology, immunology